肝癌细胞免疫治疗进展

摘要/Abstract

摘要： 肝癌的治疗目前采用手术为主的综合治疗，但是由于原发性肝癌起病隐匿，多数患者在临床诊断时已失去了手术治疗的机会，即使是手术切除后也容易复发，缺乏有效的治疗药物和手段，总的治疗效果并不理想。生物治疗作为继手术、放疗、化疗后肿瘤治疗的第四种模式，已显示了良好的应用前景。该文就肝癌的细胞免疫治疗和进展作一综述

关键词: 肝癌, 细胞免疫治疗, 进展

Abstract: At present,surgery-based comprehensive therapy plays a dominant role in the treatment of hepatocellular carcinma (HCC).However,the majority of patients had no opportunity to undergo surgical treatment when diagnosis was confirmed.Furthermore,there is a high risk of tumor recurrence for patients with HCC even after surgical resection.The overall curative effect of HCC is far from satisfaction.Cancer biotherapy has now truly matured into the fourth modality of cancer treatmnet and proved to be useful in conjunction with surgery,chemotherapy and radiotherapy.The purpose of this article is to review the current status and progress of cellular immunotherapy for HCC

Key words: Hepatocellular carcinoma, Cellular immunotherapy, Progress

中图分类号:

R735.7

杨帆(综述)，张琪，陈规划(审校). 肝癌细胞免疫治疗进展[J]. 外科研究与新技术, 2013, 2(4): 262-266.

YANG Fan, ZHANG Qi, CHEN Gui-hua. Cellular immunotherapy of hepatocellar carcinoma[J]. Surgical Research and New Technique, 2013, 2(4): 262-266.

参考文献

[1]Bruix J,Boix L,Sala M,et al.Focus on hepatocellular carcinoma[J].Cancer cell,2004,5(3):215-219.
[2] 陈规划,张琪.肝癌生物治疗的现状与展望[J].外科理论与实践,2012,17(5):434-436.
[3] Schmidt-Wolf IG,Lefterova P,Mehta BA,et al.Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells[J].Experimental hematology,1993,21(13):1673-1679.
[4] Schmidt-Wolf IG,Negrin RS,Kiem HP,et al.Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity[J].The Journal of experimental medicine,1991,174(1):139-149.
[5] Jiang J,Wu C,Lu B.Cytokine-induced killer cells promote antitumor immunity[J].Journal of translational medicine,2013,11(1):83.
[6] Huang ZM,Li W,Li S,et al.Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients[J].Journal of immunotherapy,2013,36(5):287-293.
[7] Cui J,Wang N,Zhao H,et al.Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma[J].International journal of cancer Journal international du cancer,2013.
[8] Ma Y,Xu YC,Tang L,et al.Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma:efficacy and safety[J].Experimental hematology & oncology,2012,1(1):11.
[9] Rosenberg SA,Spiess P,Lafreniere R.A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes[J].Science,1986,233(4770):1318-1321.
[10] Rosenberg SA,Packard BS,Aebersold PM,et al.Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma.A preliminary report[J].The New England journal of medicine,1988,319(25):1676-1680.
[11] Shirabe K,Motomura T,Muto J,et al.Tumor-infiltrating lymphocytes and hepatocellular carcinoma:pathology and clinical management[J].International journal of clinical oncology,2010,15(6):552-558.
[12] Takayama T,Sekine T,Makuuchi M,et al.Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma:a randomised trial[J].Lancet,2000,356(9232):802-807.
[13] Gehring AJ,Xue SA,Ho ZZ,et al.Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines[J].Journal of hepatology,2011,55(1):103-110.
[14] Koh S,Shimasaki N,Suwanarusk R,et al.A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus[J].Molecular therapy Nucleic acids,2013,2(8):e114.
[15] Sadelain M,Brentjens R,Riviere I.The basic principles of chimeric antigen receptor design[J].Cancer discovery,2013,3(4):388-398.
[16] Han EQ,Li XL,Wang CR,et al.Chimeric antigen receptor-engineered T cells for cancer immunotherapy:progress and challenges[J].Journal of hematology & oncology,2013,6(1):47.
[17] Krebs K,Bottinger N,Huang LR,et al.T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice[J].Gastroenterology,2013,145(2):456-465.
[18] Klingemann HG.Cellular therapy of cancer with natural killer cells-where do we stand?[J].Cytotherapy,2013,15(10):1185-1194.
[19] 马杰.自然杀伤细胞与肿瘤免疫治疗研究进展[J].国际妇产科学杂志,2010,37(3):208-211.
[20] Geller MA,Miller JS.Use of allogeneic NK cells for cancer immunotherapy[J].Immunotherapy,2011,3(12):1445-1459.
[21] Jiang W,Zhang C,Tian Z,et al.hIFN-alpha gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function[J].Gene therapy,2013.
[22] Palucka K,Banchereau J.Cancer immunotherapy via dendritic cells[J].Nature reviews Cancer,2012,12(4):265-277.
[23] Palmer DH,Midgley RS,Mirza N,et al.A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma[J].Hepatology,2009,49(1):124-132.
[24] El Ansary M,Mogawer S,Elhamid SA,et al.Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC[J].Journal of cancer research and clinical oncology,2013,139(1):39-48.
[25] Tada F,Abe M,Hirooka M,et al.Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma[J].International journal of oncology,2012,41(5):1601-1609.NOTICE TO INVITE CONTRIBUTIONS
   See the announcement attached inside for the details of the journal newly established.
   Notices
   Your contributions are proposed to accord with the following requirements:
   1. The contents should be up to date, scientific and logical.the materials and data, reliable and correct,the thesis or topic, clear-cut,the texts,readable and fluent, as usual, less than 4000 characters,(tables and references excluded).
   The topics and abstracts are written both in Chinese and English. The abstracts should follow the form:Objective,Methods, Results and Conclusion.And the texts,the form: Introduction, Materials and Methods,Results and Discussion.
   2. Official introduction letter are needed to show the details:Your article is the only,public contribution to us, the names of authors are incontrovertible.
   3. On the first page of your article,the following information should be included: names of each author both in Chinese and Latin letters, the top degree of record of formal schooling, working unit,corresponding author’s name, address,telephone number, Email, length of text(count in character) and the numbers of table and figure.
   4. Attached with copies of documentaries concerned, if any, when your article referring to the programs or plans funded by the State administrations or joint partnership.
   5. References of the text are proposed to be not less than 10 items written in the form: if the journals concerned, order numbers, author’s names, title[J].journal names,year,volume,number,page numbers of the first and end pages. if the books cited: [book number]. Author’s names,title[M],edition,place,publishers and year.
   6. Double-submitted contributions are not welcome, if you want to change the publisher inform us before hand.
   7. The copyrights belong to the authors,but some limited literary or text corrections are necessary to edition. The author takes sole responsibility for his views. Attach your declaration with your article if you do not allow the contents or data to be cited or reprinted.
   8. Your article should be delivered via computer to cma1992@126.com. The frist author’s name,corresponding author’s address, the serial number, if the article corrected, are needed. The corrected copies should be mailed to us in time, otherwise,that means“cancellation by the author himself ”.
   9. The article is charged RMB50.00 per title for edition. Contribution fee will be paid according to the stipulations approved by the administration, a copy of the journal with your article inside will be given to you as a present.